Drug news
Brilinta/Brilique is reviewed for ACS by IQWiG the German Health Quality Institute
Brilique/Brilinta (ticagrelor) from AstraZeneca has been reviewed by the German Institute for Quality and Efficiency in Health Care (IQWiG) ) for its use in Acute Coronary Syndrome (ACS) in comparison with conventional therapies. The Institute has come to the conclusion that ticagrelor provides considerable added benefit to patients with "mild" myocardial infarction without the typical changes in the ECG (NSTEMI), as well as to patients with unstable angina pectoris, by reducing the risk of death and myocardial infarction. However, there is no corresponding proof for "severe" myocardial infarction (STEMI), in which there are usually characteristic changes in the ECG.